Soligenix, a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, ...
Tags: Soligenix, NIAID, ThermoVax, Drs.John Carpenter
Biopharmaceutical company Soligenix has secured a contract worth $6.4m from the US Department of Health and Human Service's National Institutes of Health (NIH), for the advanced preclinical development of OrbeShield (oral beclomethasone ...
Clinical stage biopharmaceutical company Soligenix has received US patent for the vaccine thermostabilization technology, ThermoVax. The patent claims describe methods of preparing an immunologically-active adjuvant-bound, thermostable, ...
Tags: Thermovax Technology, US Patent
The US FDA has granted Soligenix fast track designation for OrbeShield for the reduction of mortality associated with gastrointestinal acute radiation syndrome (GI ARS). The oral beclomethasone 17,21-dipropionate (oral BDP) earlier ...
Tags: US FDA, Soligenix, fast track designation, OrbeShield
Soligenix has received FDA clearance for SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) investigational new drug (IND) application for the induction treatment of pediatric Crohn's disease. With the IND clearance, ...
The US FDA has granted fast track status to Soligenix's SGX203 for the treatment of pediatric Crohn's disease. SGX203 contains an active corticosteroid, beclomethasone 17,21-dipropionate (BDP), that targets local inflamed tissue. ...